Form 4: Senti Biosciences Director Brenda Cooperstone Acquires Stock Options

Director Brenda Cooperstone acquired 62,500 stock options in Senti Biosciences on July 10, 2024.

Summary

• On July 10, 2024, Brenda Cooperstone, a director of Senti Biosciences, Inc. (SNTI), acquired 62,500 stock options.
• The exercise price of these options is $0.31.
• The options vest upon the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting, contingent upon continued service.
• The expiration date for these options is July 9, 2034.
• Following the transaction, Cooperstone directly owns 62,500 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option acquisition. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. Monitoring such filings can provide insights into management's sentiment and confidence in the company's performance.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it may signal confidence in the company's future.

Key Dates